NanoViricides Reports Effectiveness Of Antiviral Clinical Drug Candidate NV-387 In An Animal Model Of Lethal Lung Infection With Respiratory Syncytial Virus
Portfolio Pulse from Benzinga Newsdesk
NanoViricides has reported that its antiviral clinical drug candidate, NV-387, has shown effectiveness in an animal model of lethal lung infection with Respiratory Syncytial Virus.
July 11, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoViricides' NV-387 has shown effectiveness in an animal model, which could potentially lead to positive market response.
The positive results from the animal model study of NV-387 could potentially lead to increased investor confidence in NanoViricides, which may result in a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100